241 related articles for article (PubMed ID: 31068788)
1. Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets.
Gómez-Ruiz M; Rodríguez-Cueto C; Luna-Piñel E; Hernández-Gálvez M; Fernández-Ruiz J
Front Mol Neurosci; 2019; 12():94. PubMed ID: 31068788
[TBL] [Abstract][Full Text] [Related]
2. Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.
Rodríguez-Cueto C; Benito C; Fernández-Ruiz J; Romero J; Hernández-Gálvez M; Gómez-Ruiz M
Br J Pharmacol; 2014 Mar; 171(6):1472-89. PubMed ID: 23808969
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3.
Rodríguez-Cueto C; Hernández-Gálvez M; Hillard CJ; Maciel P; García-García L; Valdeolivas S; Pozo MA; Ramos JA; Gómez-Ruiz M; Fernández-Ruiz J
Neuroscience; 2016 Dec; 339():191-209. PubMed ID: 27717809
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias.
Rodríguez-Cueto C; Benito C; Romero J; Hernández-Gálvez M; Gómez-Ruiz M; Fernández-Ruiz J
Pathobiology; 2014; 81(3):149-59. PubMed ID: 24642775
[TBL] [Abstract][Full Text] [Related]
5. Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3.
Rodríguez-Cueto C; Hernández-Gálvez M; Hillard CJ; Maciel P; Valdeolivas S; Ramos JA; Gómez-Ruiz M; Fernández-Ruiz J
PLoS One; 2017; 12(4):e0176521. PubMed ID: 28448548
[TBL] [Abstract][Full Text] [Related]
6. Spinocerebellar ataxia.
Klockgether T; Mariotti C; Paulson HL
Nat Rev Dis Primers; 2019 Apr; 5(1):24. PubMed ID: 30975995
[TBL] [Abstract][Full Text] [Related]
7. Disrupted Calcium Signaling in Animal Models of Human Spinocerebellar Ataxia (SCA).
Prestori F; Moccia F; D'Angelo E
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892274
[TBL] [Abstract][Full Text] [Related]
8. Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia?
Stephens GJ
J Physiol; 2016 Aug; 594(16):4631-41. PubMed ID: 26970080
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar Ataxias.
Szpisjak L; Zadori D; Klivenyi P; Vecsei L
CNS Neurol Disord Drug Targets; 2019; 18(4):279-293. PubMed ID: 30864514
[TBL] [Abstract][Full Text] [Related]
10. Aberrant Cerebellar Circuitry in the Spinocerebellar Ataxias.
Robinson KJ; Watchon M; Laird AS
Front Neurosci; 2020; 14():707. PubMed ID: 32765211
[TBL] [Abstract][Full Text] [Related]
11. Quantitative susceptibility mapping reveals alterations of dentate nuclei in common types of degenerative cerebellar ataxias.
Deistung A; Jäschke D; Draganova R; Pfaffenrot V; Hulst T; Steiner KM; Thieme A; Giordano IA; Klockgether T; Tunc S; Münchau A; Minnerop M; Göricke SL; Reichenbach JR; Timmann D
Brain Commun; 2022; 4(1):fcab306. PubMed ID: 35291442
[TBL] [Abstract][Full Text] [Related]
12. Increased protein kinase C gamma activity induces Purkinje cell pathology in a mouse model of spinocerebellar ataxia 14.
Ji J; Hassler ML; Shimobayashi E; Paka N; Streit R; Kapfhammer JP
Neurobiol Dis; 2014 Oct; 70():1-11. PubMed ID: 24937631
[TBL] [Abstract][Full Text] [Related]
13. Brain pathology of spinocerebellar ataxias.
Seidel K; Siswanto S; Brunt ER; den Dunnen W; Korf HW; Rüb U
Acta Neuropathol; 2012 Jul; 124(1):1-21. PubMed ID: 22684686
[TBL] [Abstract][Full Text] [Related]
14. Clinical, genetic and neuropathological characterization of spinocerebellar ataxia type 37.
Corral-Juan M; Serrano-Munuera C; Rábano A; Cota-González D; Segarra-Roca A; Ispierto L; Cano-Orgaz AT; Adarmes AD; Méndez-Del-Barrio C; Jesús S; Mir P; Volpini V; Alvarez-Ramo R; Sánchez I; Matilla-Dueñas A
Brain; 2018 Jul; 141(7):1981-1997. PubMed ID: 29939198
[TBL] [Abstract][Full Text] [Related]
15. [Exploration of preventive drugs for spinocerebellar ataxia using cultured cerebellar Purkinje cells].
Seki T
Nihon Yakurigaku Zasshi; 2019; 154(6):310-314. PubMed ID: 31787682
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of the Spectrum and Prevalence of Non-Motor Symptoms in Adults with Hereditary Cerebellar Ataxias.
Malek N; Makawita C; Al-Sami Y; Aslanyan A; de Silva R
Mov Disord Clin Pract; 2022 Nov; 9(8):1027-1039. PubMed ID: 36339305
[TBL] [Abstract][Full Text] [Related]
17. Ophthalmic Manifestations and Genetics of the Polyglutamine Autosomal Dominant Spinocerebellar Ataxias: A Review.
Park JY; Joo K; Woo SJ
Front Neurosci; 2020; 14():892. PubMed ID: 32973440
[TBL] [Abstract][Full Text] [Related]
18. Tissue-type plasminogen activator is an extracellular mediator of Purkinje cell damage and altered gait.
Cops EJ; Sashindranath M; Daglas M; Short KM; da Fonseca Pereira C; Pang TY; Lijnen RH; Smyth IM; Hannan AJ; Samson AL; Medcalf RL
Exp Neurol; 2013 Nov; 249():8-19. PubMed ID: 23939410
[TBL] [Abstract][Full Text] [Related]
19. Consensus Paper: Strengths and Weaknesses of Animal Models of Spinocerebellar Ataxias and Their Clinical Implications.
Cendelin J; Cvetanovic M; Gandelman M; Hirai H; Orr HT; Pulst SM; Strupp M; Tichanek F; Tuma J; Manto M
Cerebellum; 2022 Jun; 21(3):452-481. PubMed ID: 34378174
[TBL] [Abstract][Full Text] [Related]
20. Autosomal-dominant cerebellar ataxias.
Mundwiler A; Shakkottai VG
Handb Clin Neurol; 2018; 147():173-185. PubMed ID: 29325610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
